Ratings
Eternal Search · Ratings
Project Ratings
Public scoreboards for longevity projects, grouped by section. Every project carries an open eight-dimension scientific score, a breakthrough thesis, a failure thesis, and the full evidence trail behind each rating.
Project positioning
51 projects positioned by lifespan gain × overall score · all public sections
BioreplacementBioinformationDrug & Molecule DiscoveryGenetic & Cellular TherapiesAging Biology ResearchDiagnostics & BiomarkersBrain & Cognitive LongevityResearch & Funding Infrastructure
Inner ring · capital to breakeven · Outer ring · best-case upside multiple4 projects not yet positioned (missing lifespan, burn, or upside estimates): Eternal Search, Singularis: reforming the communication of scientific knowledge, Beat-FSHD, Team NovaVita
Bioreplacement
Regenerative medicine, tissue engineering, and organ replacement.
#OverallProjectSci / Brk / Inv
152.9Frontier Bio
Frontier Bio is a U.S. tissue-engineering startup pursuing two linked product lines: a patient-seeded, bioresorbable vascular graft intended for implantation and remodeling into a living blood vessel, and human tissue models such as lung and blood-brain-barrier/neural systems for preclinical testing. The central promise is plausible in concept and supported by repeated, fairly consistent company and interview claims, some partnership signals, and early preclinical/research-use positioning, but the evidence here is still weak on independent validation: most sources are company-controlled, interview-based, press-style, or investor-marketing materials, and the excerpts do not provide robust methods, sample sizes, peer-reviewed outcomes, or clinical data.Sci 46.3Brk 62.0Inv 52.9
53%
→
249.0Kind Bio
Kind Bio is a U.S. startup pursuing an "integrated organ network" platform: genetically engineered animal systems designed to grow transplantable peripheral organs while lacking higher CNS function and a normal body plan. The core promise is abundant organ supply for transplantation and, longer term, multi-organ replacement for age-related decline. The evidence is still early and mostly self-described or patent-based; there is no peer-reviewed demonstration here of functional human-ready organs, clinical efficacy, or scalable manufacturing.Sci 37.8Brk 77.6Inv 40.9
49%
→
340.7Wearable regenerative bioreactor for controlled wound healing
BioDome-R is an early-stage academic proof-of-concept for a small wearable regenerative bioreactor that creates a sealed local wound microenvironment and delivers short-term pro-regenerative cues in small-animal models. The strongest support in the provided evidence is not clinical efficacy but plausibility: related literature supports the relevance of mechanochemical control, wearable hydrogel patches, and flexible wound bioelectronics, while the project-specific evidence shows a concrete preclinical plan, explicit safety endpoints, and a narrow immediate goal of testing feasibility, tolerability, and biological response rather than claiming regeneration or translation.Sci 49.9Brk 40.0Inv 33.1
41%
→
Bioinformation
Computational biology, omics, and AI applied to biology.
Drug & Molecule Discovery
Small molecules, biologics, and therapeutic candidates.
#OverallProjectSci / Brk / Inv
153.7Team GlyNAC
Team GlyNAC appears to be a Baylor College of Medicine-associated translational longevity project built around GlyNAC, a glycine plus N-acetylcysteine supplementation strategy intended to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects. The evidence base is suggestive but still limited: there are pilot and randomized older-adult studies reporting improvements in biomarkers and some functional measures, plus mouse studies reporting lifespan, cognition, and cardiac effects, but much of the accessible material is Baylor news coverage, small early-stage studies, or preclinical work, with human durability, safety, and hard clinical outcomes still unresolved.Sci 56.8Brk 51.9Inv 52.2
54%
→
252.1Aptah Bio
Aptah Bio is a U.S.-based startup developing RNA therapeutics, centered on a U1 snRNP-modulating platform it calls RNA WiCo/RNA rejuvenation, for neurodegeneration, cancer, and other age-related diseases. The strongest project-specific evidence is still preclinical: a 2024 Scientific Reports paper reports biomarker and electrophysiology improvements for APT20TTMG in Alzheimer’s iPSC-derived neurons and SAMP8 mice, while commercial databases and company posts show a broader preclinical pipeline and claimed non-dilutive funding. The core promise is unusually broad RNA-level correction across multiple proteins and pathways, but most high-claim statements come from company-controlled or promotional sources, and there is no clinical evidence yet.Sci 57.3Brk 57.0Inv 44.6
52%
→
347.2Team Twilight
Team Twilight is a U.S. biotech startup developing active immunotherapies against pathological proteins, especially HERV-K-linked targets in ALS, with broader stated ambitions in Alzheimer’s, Parkinson’s, and chronic pain. The strongest direct evidence is the company’s own claims about its Ambifect Fc-fusion platform, leadership, and intended indications; the stronger independent evidence sits one layer back, supporting HERV-K as an ALS-related biomarker and mechanistic target class rather than validating Team Twilight’s product. The core uncertainty is that no clinical efficacy data for Team Twilight’s program are provided here.Sci 48.8Brk 52.7Inv 42.4
47%
→
447.0NYC-Vita
NYC-Vita is a Mount Sinai-led, New York City pilot longevity trial that appears to combine home-based exercise, daily spermidine, and low-dose rapamycin or lamivudine in adults roughly 65-80, with the stated goal of improving immune function, muscle strength, cognition, and overall healthspan. The project has clear institutional backing and XPRIZE Healthspan semifinalist status, but the evidence here is mostly press, partner-content, and social posts plus secondary media coverage; there are no published trial results, and even basic questions about efficacy, mechanism, attribution, and safety remain unresolved.Sci 45.7Brk 43.1Inv 50.5
47%
→
Genetic & Cellular Therapies
Gene therapy, CRISPR, stem cells, and senolytics.
#OverallProjectSci / Brk / Inv
162.0Rejuvenate Bio
Rejuvenate Bio is a San Diego startup developing one-time AAV gene therapies for age-related and chronic disease, with the clearest disclosed programs in canine mitral valve disease, desmoplakin arrhythmogenic cardiomyopathy, and partial epigenetic reprogramming. The upside case is unusually ambitious: use liver-directed or systemic gene delivery to create durable, body-wide effects from secreted factors such as FGF21 or from inducible OSK reprogramming. The evidence is still mostly preclinical, often company-reported, and the strongest claims remain limited by mouse or small pilot dog data rather than human validation.Sci 59.0Brk 68.0Inv 60.8
62%
→
257.7Armatus Bio
Armatus Bio is a U.S. late-preclinical biotech developing AAV-delivered engineered microRNA therapies for autosomal dominant neuromuscular diseases, with lead programs in CMT1A and FSHD. The strongest project-specific evidence is still preclinical: a 2026 Molecular Therapy: Nucleic Acids paper on AAV9 RNAi for CMT1A in mice and nonhuman primates, a 2026 assay-development paper for potency testing, company and partner press releases on TVR110 and ARM-201, and a pending 2025 PCT patent co-listed with Nationwide Children’s Hospital. The core bet is plausible but unproven in humans, and the main risks are delivery to the right cells at tolerable doses, over-silencing/off-target effects, AAV toxicology, manufacturing consistency, and crowded RNAi/IP competition in both DUX4 and PMP22.Sci 65.7Brk 57.5Inv 50.9
58%
→
355.9Rejuvenation through Low Frequency
UT Health San Antonio’s "Rejuvenation Through Low Frequency Ultrasound" project is a US-based translational longevity effort testing whether low-frequency ultrasound can reverse cellular senescence without destroying cells. The strongest direct evidence is a 2025 Aging Cell paper with that core claim in its title and authors tied to UTMB and UT Health San Antonio, plus a 2025 university news report that the team became an XPRIZE Healthspan semifinalist and Milestone 1 awardee. The main caveat is that the public evidence here is still thin on quantitative outcomes, with human efficacy and safety not yet established.Sci 55.1Brk 62.1Inv 52.8
56%
→
455.0RenewalBio
RenewalBio is an Israel-based Weizmann spinout and startup developing "stembroids": human iPSC-derived developmental models intended to generate DNA-matched transplantable cells and tissues, with the clearest near-term stated target being hematopoietic stem cell applications for bone marrow failure and related transplant settings. The central promise is large-scale production of authentic, patient-matched replacement cells using embryo-like self-organization rather than conventional expansion, but the evidence here is mostly company, investor, media, and profile material rather than peer-reviewed efficacy or clinical data, so the project should be treated as ambitious and preclinical rather than validated.Sci 52.5Brk 70.2Inv 47.8
55%
→
Aging Biology Research
Mechanisms of aging, hallmarks, and model organism studies.
Diagnostics & Biomarkers
Aging clocks, biomarkers, and screening tools.
#OverallProjectSci / Brk / Inv
147.1Japan Longevity Consortium
Japan Longevity Consortium is a Japan-based academic consortium led from Juntendo University that is promoting a biomarker-guided, multi-component “Scientific Zen” healthspan program combining washoku-style diet, mild fasting, exercise, yoga/breathing, TEAS, far-infrared therapy, supplementation, and gut-focused management to improve cognition, immune function, and muscle function. The strongest signals are a senior university team, XPRIZE Healthspan Top 40 semifinalist status, and self-reported preliminary observational findings on epigenetic-age and autonomic outcomes; the main constraint is that the core efficacy claims are currently presented mostly on the consortium’s own site or institutional announcements, with limited methodological detail and no clearly linked peer-reviewed validation of the full program.Sci 42.1Brk 41.9Inv 54.6
47%
→
237.9CHANGS
CHANGS is a newly announced 2025 Chulalongkorn University-BGI collaboration in Thailand focused on healthy aging, using omics and AI-based bioinformatics to analyze elderly health, collect volunteer samples and clinical data, and reportedly build outputs such as multi-omic aging measures and organ-aging models. The evidence supports that the project exists and has institutional backing, but not that it has yet produced validated biomarkers, intervention results, or clinical utility.Sci 38.5Brk 36.5Inv 38.4
38%
→
Brain & Cognitive Longevity
Neurodegeneration, cognitive resilience, and brain aging.
#OverallProjectSci / Brk / Inv
156.9Axxium Life
Axxium Life presents itself as a developer of AI-powered active immunotherapy biologics aimed first at Alzheimer’s prevention and other chronic diseases, using peptide-based vaccines intended to induce patients’ own antibodies against targets such as amyloid-beta and alpha-synuclein. The strongest external support in the provided evidence is not for Axxium’s current flagship claim directly, but for related Vaxxinity/United Biomedical-linked programs: a phase 2a Alzheimer’s study, first-in-human and phase 1 alpha-synuclein studies, mouse synuclein data, and a monkey PCSK9 vaccine study. The main caution is that the most ambitious claims, including a privately controlled Phase 3 Alzheimer’s-prevention position and AI platform performance, are self-reported on company pages and not independently validated in the excerpt.Sci 65.0Brk 60.5Inv 47.6
57%
→
245.1VITA (Hospital del Mar Research
VITA is a Barcelona-based, XPRIZE Healthspan semifinalist project from Hospital del Mar Research Institute, CRG, and IrsiCaixa that proposes a multimodal healthy-aging intervention centered on lamivudine, EGCG, and lifestyle change for older adults at risk of cognitive decline. The strongest public evidence is institutional: funding/selection announcements in May 2025, follow-on reporting tied to prior PENSA work, and a Jan-Jun 2026 recruitment page for a lifestyle-plus-EGCG study in adults aged 60-80 with subjective cognitive concerns. That supports real institutional activity and clinical intent, but not efficacy; public evidence still looks early, non-peer-reviewed, and partly inconsistent about whether lamivudine is already in the human study arm.Sci 46.0Brk 40.2Inv 47.4
45%
→
340.6Mitochondrial Bioenergetics and Ketone
Mitargos appears to be a US startup commercializing an R-1,3-butanediol ketone drink, MiDR1V3, and linking it to a UC San Diego-led XPRIZE Healthspan semifinalist project that plans to test whether ketone-based interventions can improve mitochondrial function and physical, cognitive, and immune outcomes in older adults; however, the supplied evidence is mostly patent/IP and review literature plus a company-linked press release, so project-specific efficacy remains unproven.Sci 43.8Brk 34.9Inv 41.5
41%
→
434.7LiGHT Team (Lithium as a
LiGHT Team appears to center on low- or trace-dose lithium as a neuroprotective strategy for dementia, Parkinson’s disease, and related brain-aging conditions. The provided record supports substantial idea generation and patent activity, plus limited preclinical signal, but not convincing human efficacy. The main attraction is that lithium is biologically active, cheap, and already medically familiar; the main problem is that standard lithium has a narrow therapeutic window and meaningful renal, thyroid, and neurological toxicity, so the project only matters if much lower exposures still produce real CNS benefit.Sci 34.4Brk 34.8Inv 34.9
35%
→
Research & Funding Infrastructure
Meta-science: tools, publishing, funding, and evaluation.
#OverallProjectSci / Brk / Inv
155.0NUS Academy for Healthy Longevity
The NUS Academy for Healthy Longevity appears to be a Singapore-based precision-geromedicine hub at NUS that combines clinical-trial infrastructure, biomarker-oriented research, education, and public-facing convening around healthy longevity. The strongest direct evidence is not intervention efficacy but organizational build-out: a clinical trial centre opened in 2025, multiple recruitment-stage or feasibility studies are described, and peer-reviewed outputs include a conceptual framework (HELO), a Singapore population survey on healthy-longevity knowledge and interest, and adjacent aging-biomarker studies. Most claims about impact, personalization, and biological-age reduction remain promotional, early-stage, or non-comparative rather than validated in robust human outcome trials.Sci 55.2Brk 51.3Inv 57.3
55%
→
250.4Eternal Search
Eternal Search is a live longevity-focused funding and intelligence platform operated by Open Longevity (California 501(c)(3) nonprofit) that claims to reduce manual opportunity discovery by using AI-assisted curation, verification, deduplication, and relevance scoring across grants, fellowships, infrastructure support, investors, and related field signals. The strongest evidence supports it as an operating research-and-funding infrastructure product with public listings, basic traction metrics, and an API-oriented roadmap; the weakest point is that its core accuracy, coverage, and time-saving claims are self-described rather than independently validated.Sci 49.1Brk 44.6Inv 55.0
50%
→
348.7Singularis: reforming the communication of scientific knowledge
Singularis is an early-stage scientific-knowledge platform that argues conventional papers are a bottleneck for both human readers and AI systems, and proposes converting papers into structured argumentation graphs and nanopublication-like units that link hypotheses, methods, results, conclusions, and evidence. The concrete product evidence is a beta system for PDF upload, knowledge-graph visualization, and graph-based chat, plus public claims about AI-generated paper graphs and source-linked annotations. The core idea is plausible as research infrastructure, but current evidence shows positioning and prototype functionality more clearly than validated accuracy, adoption, or field-level impact.Sci 45.9Brk 55.5Inv 47.0
49%
→
445.9Pentara Brain Stride
Pentara Brain Stride appears to be a clinical-trial biostatistics and data-integrity offering focused on neurodegenerative disease studies, especially regulatory-facing trial design, analysis, and fraud detection. The core claim is not a new therapy but that better endpoint selection, statistical design, programming, data management, and anomaly detection can improve the truthfulness and decision value of brain-related trials. The evidence supports domain specialization and relevant personnel, but it is mostly self-description from company pages rather than independent validation, and no verified outcome metrics are provided.Sci 49.6Brk 31.9Inv 51.5
46%
→